Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma

Glioblastoma Clinical Trial

Official title:

A Phase I Study of Th-1 Dendritic Cell Immunotherapy in Combination With Standard Chemoradiation for the Adjuvant Treatment of Adult Glioblastoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04552886
• Other study ID #: 8148
• Status: Completed
• Phase: Phase 1
• Start date: October 11, 2021
• Est. completion date: December 1, 2023

Study information

• Verified date: January 2024
• Source: The Cooper Health System
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Effective treatments are desperately needed for glioblastoma (GBM) patients. This phase I clinical trial assesses the safety of a novel personalized dendritic-cell vaccine administered to GBM patients shortly after completing standard-of-care treatments. Secondary outcomes will evaluate patient progression-free survival and overall survival.

Description:

This is a single arm (non-randomized) first-in-man pilot study to evaluate the safety and feasibility of delivering a dendritic cell vaccine in nine to twenty-four (n=9-24) adult patients diagnosed with glioblastoma (GBM) after undergoing neurosurgical tumor resection, and in whom a neuropathological diagnosis has been established. Standard of care chemotherapy and radiation therapy shall be followed as per routine neuro-oncologic paradigms after which patients enrolled into this study will receive a personalized vaccine beyond standard of care. Effective adjuvant therapies are urgently needed for these patients given that standard of care is rarely successful in preventing recurrence among GBM patients, nor death among relapsed patients with this very poor-prognosis tumor type. The study is constructed in a 3+3 algorithm for three steps of dose escalation with rigorous and mandatory safety monitoring.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: December 1, 2023
• Est. primary completion date: December 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Provision of signed and dated informed consent form

2. Stated willingness to comply with all study procedures and availability for the duration of the study

3. Male or female, aged 18 years and older

4. Diagnosed with glioblastoma (GBM) deemed to be potentially resectable and who are deemed to be good candidate for postoperative adjuvant chemo and radiation therapy. This may include patients whose tumors are deemed suitable for gross total resection as well as patients whose tumors are deemed partially resectable and who undergo partial resection followed by adjuvant therapy. [neoadjuvant therapy is rarely if ever given]..

5. Ability to adhere to the bi-weekly injections of DC vaccine regimen

6. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 12 weeks following discontinuations of last vaccination. Must have a negative serum pregnancy test prior to first treatment.

7. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner during study participation and for an additional 12 weeks following discontinuations of last vaccination.

8. Presented at Tumor Board for review and consensus of Multidisciplinary group to proceed with enrollment.

9. Adequate kidney, liver, bone marrow function, and immune function, as follows:

1. Hemoglobin = 8.0 gm/dL

2. Absolute neutrophil count (ANC) = 1,500 cells/mm3

3. Platelet count = 100,000 /mm3

4. Lymphocyte count greater than 500/L

5. Glomerular filtration rate (GFR) > 60 mL/min/m2 and Creatinine < 1.5mg/dl

i. For males = (140 - age[years]) x (body weight [kg]) (72) x (serum creatinine [mg/dL] ii. For females = 0.85 x male value f. Total bilirubin = 1.5 times upper limit of normal (ULN), g. Aspartate transaminase AST (SGOT) and alanine aminotransferase ALT (SGPT) = 2.5 times the ULN h. Albumin >2g/dL i. (IgM), surface antibody and antigen, Hepatitis B and C antibody. j. Negative HIV status

10. Eastern Cooperative Oncology Group (ECOG) performance status = 2.

Exclusion Criteria:

1. Locally advanced tumors deemed unresectable and/or recurrent tumors after prior vaccination.

2. Use of non-standard post-operative treatment regimen, as defined by the Stupp protocol: postoperative chemoradiation and initiation of temozolomide (TMZ). The use of a tumor treatment field (TTF) device with adjuvant TMZ is at the discretion of the investigator.

3. Female patients who are pregnant, breast feeding, or of childbearing potential without a negative pregnancy test prior to baseline. Post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.

4. Patients unwilling or unable to comply with the protocol or provide informed consent.

5. Any severe or uncontrolled medical condition or other condition that could affect participation in this study, including but not limited to: hyper/hypothyroidism, systemic autoimmune disorders, untreated viral hepatitis or autoimmune hepatitis.

6. Concurrent or expected need for therapy with corticosteroids during the vaccination phase of the study.

7. Treatment with another investigational drug or other intervention outside of the prespecified standard of care for GBM.

8. Patients suffering from active HIV disease.

Related Conditions & MeSH terms

• Glioblastoma

Intervention

Biological:
• TH-1 Dendritic Cell Immunotherapy
Adult patients with histopathologically diagnosed glioblastoma will be eligible for this novel, personalized dendritic cell vaccine after completing standard of care chemoradiation.

Locations

Country	Name	City	State
United States	Cooper University Hospital	Camden	New Jersey
United States	Memorial Hermann- Texas Medical Center	Houston	Texas

Sponsors (3)

Lead Sponsor	Collaborator
The Cooper Health System	Baylor College of Medicine, Philadelphia College of Osteopathic Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and potential toxicity of Th-1 dendritic cell immunotherapy	Patients will be monitored for adverse events as dictated by CTCAE version 5.	Two years
Secondary	Overall survival of patients receiving Th-1 dendritic cell immunotherapy	Length of survival for patients who receive this vaccine will be tabulated.	Minimum 2 years from time of diagnosis
Secondary	Progression-free survival of patients receiving Th-1 dendritic cell immunotherapy	If there is tumor recurrence, the time from diagnosis until recurrence will be collected	Minimum 2 years from time of diagnosis